drugset
Drugs / Norovirus Bivalent (GI.1 / GII.4) Vaccine
last change Dec 2020 re-read 3 minutes ago

Norovirus Bivalent (GI.1 / GII.4) Vaccine

Vaccine

Developed for
norovirus infectious disease
Investigated by
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China · Zhengzhou University

Trials 1

today NCT04188691 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04188691 Nov 2019 → Dec 2020 norovirus infectious disease National Vaccine and Serum Institute, China Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Norovirus Bivalent (GI.1 / GII.4) Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04188691 ↗
Modality Vaccine “Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenulapolymorpha)” NCT04188691 ↗
Route Intramuscular “administered intramuscularly according to a 0, 28，（56） day vaccination schedule” NCT04188691 ↗